SLC25 线粒体载体家族的癌症治疗潜力和预后价值：综述。
Cancer Therapeutic Potential and Prognostic Value of the SLC25 Mitochondrial Carrier Family: A Review.
机构信息
School of Queen Mary, Jiangxi Medical College, Nanchang University, Nanchang, China.
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China.
出版信息
Cancer Control. 2024 Jan-Dec;31:10732748241287905. doi: 10.1177/10732748241287905.
Transporters of the solute carrier family 25 (SLC25) regulate the intracellular distribution and concentration of nucleotides, amino acids, dicarboxylates, and vitamins within the mitochondrial and cytoplasmic matrices. This mechanism involves changes in mitochondrial function, regulation of cellular metabolism, and the ability to provide energy. In this review, important members of the SLC25 family and their pathways affecting tumorigenesis and progression are elucidated, highlighting the diversity and complexity of these pathways. Furthermore, the significant potential of the members of SLC25 as both cancer therapeutic targets and biomarkers will be emphasized.
溶质载体家族 25（SLC25）的转运蛋白调节核苷酸、氨基酸、二羧酸和维生素在线粒体和细胞质基质中的细胞内分布和浓度。这种机制涉及线粒体功能的变化、细胞代谢的调节以及提供能量的能力。在这篇综述中，阐明了 SLC25 家族的重要成员及其影响肿瘤发生和进展的途径，突出了这些途径的多样性和复杂性。此外，还将强调 SLC25 成员作为癌症治疗靶点和生物标志物的重要潜力。
Zotero 插件